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Abstract
Objective To evaluate the quality of contemporary sec-
ondary prevention of cardiovascular disease (CVD), and
the differences between six ethnic groups in a large, obser-
vational cohort.
Design We included participants with a self-reported his-
tory of CVD from the HEalthy LIfe in an Urban Setting
(HELIUS) study, which investigates inequalities in health
between six ethnic groups living in Amsterdam, the Nether-
lands. We quantified the proportions of patients who were
at the preventive treatment goal according to the guidelines
of the European Society of Cardiology for six risk factors:
hypertension, dyslipidaemia, smoking, overweight, physi-
cal inactivity and diabetes mellitus, and the use preventive
medication.
Results Of 22,165 participants, 1163 (5%) reported a his-
tory of CVD. Mean age was 54 years. Overall, 69% had
a systolic blood pressure of <140 mm Hg, and 42% had
a low-density lipoprotein (LDL) cholesterol of <2.5 mmol/l.
Non-smoking was found in 67%. Body mass index (BMI)
<25 kg/m2 was found in 24%, and 54% reported adequate
physical activity. The mean number of risk factors per pa-
tient was three (±1.1) out of six, and only 2% had all risk
factors on target. Across the ethnic groups, non-smoking
was more prevalent in the Ghanaian and Moroccan groups
than in the Dutch (p < 0.001 and p = 0.001, respectively);
BMI <25 kg/m2 and adequate physical activity were less
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prevalent among all ethnic minority groups compared with
the Dutch group.
Conclusion We found large treatment gaps in secondary
prevention of CVD. Ethnic differences in risk factors were
found; however, strategies to improve overall risk factor
management may be mandated before designing ethnic-spe-
cific strategies.
Keywords Cardiovascular disease · Secondary
prevention · Risk factors · Ethnicity · HELIUS study
Introduction
Individuals with established cardiovascular disease (CVD)
have a high risk of mortality and recurrent morbidity [1–3].
Secondary prevention of CVD is effective in decreasing
this risk, and has been shown to reduce healthcare costs,
increase economic productivity and improve quality of life
[4, 5].
The European Society of Cardiology (ESC) guideline
on CVD prevention provides clear goals for primary and
secondary CVD prevention [6]. The implementation of
this guideline in daily practice has been evaluated by
international surveys. The recent EUROASPIRE IV sur-
vey (2012–2013) found that the majority of 7998 patients
with established CVD (hospital arm) do not achieve the
lifestyles, risk factor levels, and therapeutic goals rec-
ommended in the 2012 ESC guideline [7]. However, the
EUROASPIRE surveyed recruited patients from selected
hospitals, and the findings on secondary prevention may
differ in a population that includes more ethnic minority
groups.
Ethnic minority groups often have a higher risk of CVD
due to the influence of genetic, environmental, social and
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Fig. 1 Flowchart: selection
study population from HELIUS
cultural factors [8, 9]. For example, in the UK, CVD mor-
tality rates among South-Asian men are higher than those
of the general population,[10] and hypertension is highly
prevalent among adults of African origin in the UK com-
pared with European adults [11]. Amsterdam, the Nether-
lands, is home to multiple ethnic minority groups, with
approximately 35% of its citizens being first- or second-
generation non-Western immigrants [12].
The aim of our study was to evaluate the quality of sec-
ondary prevention in individuals with CVD by quantifying
the number of secondary prevention goals achieved and the
prescription of secondary prevention medication, and subse-
quently to analyse the inequalities in secondary prevention
between six ethnic groups.
Methods
Study population
The HEalthy LIfe in an Urban Setting (HELIUS) study is
a large, multi-ethnic, population-based cohort study in Am-
sterdam, the Netherlands. The HELIUS study aims to inves-
tigate ethnic inequalities in health, focusing on three major
causes of disease: cardiovascular disease, mental health,
and infectious disease. The details of the study have been
described elsewhere [13]. In brief, from January 2011 to
November 2015, HELIUS included similar numbers of in-
dividuals (aged 18–70 years) from six ethnic groups: South-
Asian Surinamese, African Surinamese, Ghanaian, Turk-
ish, Moroccan and Dutch. Subjects were randomly sampled
through the municipality register of Amsterdam, and strat-
ified by ethnicity. Data were collected by questionnaire,
physical examination and biological samples. The study
protocols were approved by the Academic Medical Center
Ethics Review Board, and all participants provided written
informed consent.
In total, 22,165 participants were included for whom ade-
quate data from the questionnaire and the physical examina-
tion were available. Due to very small numbers, participants
with an unknown ethnic origin, unknown Surinamese ori-
gin or Java-Indonesian Surinamese were excluded. For the
current analysis, we selected all participants who reported
a history of CVD (‘patients’) (Fig. 1).
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Table 1 Characteristics of CVD patients recruited from the HELIUS cohort
Total Dutch South Asian African Ghanaian Turkish Moroccan
Surinamese Surinamese














Age, years 54 (±10.0) 59 (±9.0) 56 (±9.7) 56 (±8.7) 52 (±8.2) 50 (±9.4) 49 (±11.1)
Age at CVD
event, years
47 (±10.8) 52 (±10.1) 48 (±10.3) 48 (±10.9) 45 (±9.2) 43 (±9.6) 41 (±12.1)












396 (35%) 58 (35%) 116 (42%) 64 (29%) 15 (14%) 110 (46%) 33 (25%)
Stroke 372 (33%) 66 (40%) 85 (31%) 108 (49%) 28 (27%) 51 (22%) 34 (26%)




625 (55%) 109 (65%) 181 (66%) 135 (61%) 54 (51%) 110 (46%) 36 (28%)
Antithrombotics 548 (48%) 126 (75%) 169 (61%) 111 (50%) 19 (18%) 93 (39%) 30 (23%)
Lipid-lowering
medication
553 (49%) 109 (65%) 175 (63%) 105 (48%) 32 (30%) 102 (43%) 30 (23%)
History of dia-
betes mellitus
321 (28%) 28 (17%) 128 (46%) 52 (24%) 25 (24%) 55 (23%) 33 (25%)
Diabetes medi-
cation
268 (83%) 22 (79%) 113 (88%) 46 (88%) 17 (68%) 46 (84%) 24 (73%)
CVD cardiovascular disease, BP blood pressure
Measurements
A history of CVD was based on three questions: 1) Have
you ever had a heart attack? 2) Have you ever had a stroke?
3) Have you ever had a catheter intervention or bypass
surgery on heart or legs? The third question was defined
as revascularisation. Educational level was based on the
highest qualification obtained in the Netherlands or abroad
and was classified into two groups: 1) no or lower educa-
tion (no schooling, vocational schooling or lower secondary
schooling), 2) intermediate or higher education (interme-
diate vocational schooling, intermediate/higher secondary
schooling, higher vocational schooling or university). Cur-
rent smoking status was self-reported as yes or no. Physi-
cal activity was self-reported using the Short Questionnaire
to Assess Health-Enhancing Physical Activity (SQUASH)
questionnaire [14]. Adequate physical activity (yes/no) is
defined as reaching the international goal for physical ac-
tivity (moderate- to high-intensity physical activity for at
least 30 min per day on at least five days per week).
Medication was identified and categorised using the
Anatomical Therapeutic Chemical (ATC) classification
system: blood pressure (BP) lowering medication, an-
tithrombotics, lipid-lowering medication, and medication
for diabetes mellitus. The BP was measured twice using
a validated automated sphygmomanometer after five min-
utes of rest, and the mean of the two measurements was
used. Height and weight were measured in light clothes
without shoes. Body mass index (BMI) was calculated as
weight (kg) divided by height squared (m2). Fasting blood
samples were drawn to determine low-density lipoprotein
(LDL) cholesterol, glucose and HbA1c.
Goals for secondary prevention were defined according
to the 2012 ESC guidelines [6]: 1) systolic BP <140 mm Hg;
2) LDL cholesterol <1.8 mmol/l; 3) non-smoking; 4) BMI
<25 kg/m2; 5) adequate physical activity 6) fasting glucose
<7 mmol/l (patients without diabetes mellitus (DM)) or
HbA1c < 48 mmol/mol (patients with DM). As the goal
for LDL cholesterol was changed from <2.5 mmol/l to
<1.8 mmol/l in 2012, we used <2.5 mmol/l for our main
analysis, as the majority of the patients had experienced
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Table 2 Prevalence of achieving CVD prevention goals according to
the ESC guidelines 2007 and 2012
Total population
Blood pressure
SBP <140 mm Hg 786/1132 (69%)
SBP <140 mm Hg with medication 391/786 (50%)
SBP ≥140 mm Hg 346/1132 (31%)
SBP ≥140 mm Hg with medication 232/346 (67%)
Cholesterol
LDL cholesterol <2.5 mmol/l 470/1112 (42%)
LDL cholesterol <2.5 mmol/l with medication 339/470 (72%)
LDL cholesterol ≥2.5 mmol/l 642/1112 (58%)
LDL cholesterol ≥2.5 mmol/l with medication 204/642 (32%)
LDL cholesterol <1.8 mmol/l 164/1112 (15%)
LDL cholesterol <1.8 mmol/l with medication 127/164 (77%)
LDL cholesterol ≥1.8 mmol/l 948/1112 (85%)
LDL cholesterol ≥1.8 mmol/l with medication 416/948 (44%)
Non smoking 755/1122 (67%)
Healthy weight (BMI <25 kg/m2) 270/1134 (24%)
Physical activity (≥30 min/5days/week) 613/1136 (54%)
Diabetes mellitus regulation
Self-reported DM 321/1116 (29%)
Glucose-lowering medication 252/321 (79%)
HbA1c < 48 mmol/mol 105/315 (33%)
Glucose regulation (in patients without self-reported DM)
Glucose <7 mmol/l 747/768 (97%)
CVD cardiovascular disease, SBP systolic blood pressure, LDL lower
density lipoprotein, BMI body mass index, DM diabetes mellitus
their events before 2012. Differences between ethnic groups
were presented as prevalence ratios, with the Dutch group
as the reference.
Statistical methods
Continuous variables were presented as mean with stan-
dard deviation for normally distributed data, and as median
with quartiles (Q1 and Q3) for non-normally distributed
data. Categorical variables were presented as frequencies
and percentages. Prevalence ratios and their corresponding
95% CI were calculated and graphs were created to dis-
play ethnic differences in the prevalence of achieved goals.
Comparisons between groups were made by independent
sample t-tests, one-way ANOVA (and corrected for multi-
ple testing using the Bonferroni method) and Fisher’s exact
tests, as applicable. All statistical tests were two-tailed and
a p value of <0.05 was used to indicate statistical signif-
icance. We used IBM SPSS Statistics, version 22.0 (IBM
Corp., Armonk, NY, USA).
Results
A total of 1136 patients, with a mean age of 54 years (±10.0)
reported a history of CVD, including 276 (24%) South-
Asian Surinamese, 237 (21%) Turkish, 221 (19%) African
Surinamese, 167 (15%) Dutch, 130 (11%) Moroccan, and
105 (9%) Ghanaian patients. Of these, 501 (44%) were fe-
male. The median time from the CVD event to baseline
examination was seven years (3–12 years). Most partici-
pants had had no education or only lower education (67%).
The proportion of Dutch with intermediate or higher edu-
cation was significantly greater compared with all the other
ethnic groups (61% vs. ~28%, p < 0.001). Comparison of
each ethnic group individually with the Dutch group also
resulted in p values <0.001.
In total, 372 (33%) patients reported using the combi-
nation of BP-lowering, antithrombotic and lipid-lowering
medication, and there were 371 (33%) patients who did
not use any medication for secondary prevention of CVD.
Dutch and South-Asian Surinamese had the highest use of
medication while Ghanaians and Moroccans had the lowest
use of medication (Table 1).
Table 2 presents overall risk factor control according
to goals as defined by the ESC [6]. Of all patients, 786
(69%) had a systolic BP <140 mm Hg and 470 (42%) pa-
tients had an LDL cholesterol <2.5 mmol/l, of whom 339
(72%) reported the use of lipid-lowering medication. There
was a substantial variance in the different aspects of healthy
behaviour: 67% reported non-smoking, 24% had a BMI
<25 kg/m2, and an adequate level of physical activity was
reported in 54%. In patients who did not report a history
of DM and/or medication use for DM, we found 21 (3%)
patients with fasting plasma glucose levels ≥7 mmol/l, i. e.
not yet diagnosed diabetes.
The mean number of risk factors that were not on target
per patient was 3 (±1.1) out of a maximum of six. This
varied from 0 risk factors off target in 2% of the patients,
to 4% of the patients with five risk factors off target (Fig. 2).
Fig. 3 presents the prevalence ratios of cardiovascu-
lar goals per ethnic group. Systolic BP <140 mm Hg was
most frequently observed in Moroccan, Turkish and Dutch
patients (~76%), and least frequently in Ghanaian pa-
tients (48%). The proportion of patients with a systolic BP
<140 mm Hg was significantly different between Ghana-
ians and Dutch (p < 0.001). The proportion of patients
with an LDL cholesterol <2.5 mmol/l ranged from 38 to
46% across groups (p = 0.2 between groups). Non-smok-
ing rates varied from 91% in Ghanaian (p < 0.001 vs.
Dutch 65%) to 56% in African Surinamese patients (p =
0.8). A BMI of <25 kg/m2 was found in 11% of Turkish
(p < 0.001 vs. Dutch 34%), 19% of Ghanaian (p = 0.09
vs. Dutch) and 28% of Moroccan patients (p = 0.02 vs.
Dutch). Physical activity was most frequently on target in
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Fig. 2 Distribution of number of risk factors off target per patient
Dutch (73%), followed by African Surinamese (58%, p =
0.05), South-Asian Surinamese (55%, p = 0.002), Ghanaian
(51%, p = 0.003), Turkish (44%, p < 0.001), and Moroccan
patients (42%, p < 0.001). There were differences between
ethnic groups in reported DM: Dutch patients had a low
prevalence (17%) compared with South-Asian Surinamese
(46%) patients (p < 0.001).
Discussion
In our study, performed in individuals with a history of
CVD in a large contemporary population-based cohort, we
found that the proportion of risk factors on target for sec-
ondary prevention were disappointing, both for the total
group and when stratified by ethnicity.
Overall, the mean number of risk factors that were not on
target per patient was three (±1.1) out of six. The number
of patients without any risk factors off target was strik-
ingly low – only 2% (Fig. 2). There were substantial dif-
ferences between ethnic groups in risk factor control. Non-
smoking was most often seen in Ghanaians and Moroc-
cans. Only a small proportion of Dutch were on target for
healthy weight (34%), although most Dutch reported ade-
quate physical activity levels (73%). This treatment gap in
achieving lifestyle-related risk factors was even larger in all
other ethnic groups.
We found that the use of BP-lowering medication, an-
tithrombotics and lipid-lowering medication was less fre-
quently reported in HELIUS when compared with a Dutch
multicentre study. Only 55% of the patients used BP-lower-
ing medication, 46% used antithrombotics, and 48% of the
patients used lipid-lowering medication, as compared with
89% of the patients using beta-blockers, 92% acetylsalicylic
acid (antithrombotics), and 93% lipid-lowering medications
at the time of discharge in 2471 patients in the Netherlands
[15]. These differences may be explained by the fact that
HELIUS included participants from the general population
with an average time since event of seven years, instead
of selecting patients at hospital discharge. It is likely that
our results give a more realistic impression of secondary
prevention in daily practice.
When we compared our findings with the recent EU-
ROASPIRE IV, both studies conclude that secondary pre-
vention goals are not optimally met in clinical practice,
although we did find some differences. First, smoking rates
were lower in EUROASPIRE IV, with 84% non-smokers
compared with 67% in HELIUS. However, smoking rates
varied widely between ethnic groups and are likely to be
associated with environmental, social and cultural factors
[8]. Second, the goal of <2.5 mmol/l for LDL cholesterol
was met in 44% of the patients in our study, while EU-
ROASPIRE IV reported 58% of patients achieving this goal.
Potential explanations include the much lower use of lipid-
lowering medication in our study population, which may
yet again be related to the difference in time elapsed since
the event.
The HELIUS cohort consists of participants from six
different ethnic groups. Our study shows a wide variation
between these groups in the prevalence of risk factors and
the use of secondary prevention drugs. Gijsberts et al. have
previously reported ethnic-specific differences in a cohort
consisting of Dutch, Chinese, Indians and Malays. They
found significant ethnic differences in biomarkers for the
severity of coronary artery disease [16]. In our study, Dutch
patients were found to have better risk factor control and
a higher prevalence of medication use. This could be re-
lated to socioeconomic status, which has been shown to be
related to risk factor management and control in secondary
prevention [17]. In HELIUS we found that the proportion
of Dutch patients with an intermediate to higher education
(a surrogate for economic status) is much greater than in
the other ethnic groups, which could explain some of the
differences between Dutch and other ethnic groups.
It has been suggested that ethnic-specific interventions
are needed to optimise risk factor control in patients of dif-
ferent ethnic origin [18, 19]. However, control of risk fac-
tors in our study was poor overall, regardless of ethnicity.
Based on our findings, strategies to improve overall risk fac-
tor management, or with special attention for patients with
a lower social economic status, may be mandated before
designing ethnicity-specific strategies.
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Fig. 3 Prevalence ratios of
achievement of secondary pre-
vention goals among ethnic
groups
Strengths and limitations
There are several strengths to our study. First, we used
a robust sampling technique from the source population
through the municipality register of Amsterdam, stratified
by ethnicity. This approach allows for a non-selective, com-
munity-recruited study sample as opposed to surveys that
recruit their patients in selected hospitals or outpatient clin-
ics, although we cannot exclude selection bias. Second, by
design, HELIUS included ethnic minority groups, who are
often underrepresented in epidemiological studies in high-
income countries. Some limitations of our study require
consideration. First, the HELIUS data are cross-sectional,
and CVD risk factor changes over time could not be evalu-
ated. Second, the diagnosis of CVD was self-reported, po-
tentially leading to either under-reporting or over-reporting.
For example, the overall percentage of women in HELIUS
is relatively high (44%), especially in African Surinamese,
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Ghanaian, Turkish and Moroccan patients. Possibly, these
participants may have over-reported having a diagnosis of
CVD. However, previous studies have shown a high degree
of specificity for self-reported CVD and stroke [20, 21].
Third, participants older than 70 years were not included in
HELIUS, potentially resulting in a lower proportion of indi-
viduals with CVD, as the prevalence of CVD increases with
age. Fourth, in our current analyses we did not adjust for the
difference in educational level. Socioeconomic status likely
impacts on adherence to preventive treatments in all eth-
nic groups. However, we believe that even if a significant
proportion of the ethnic differences were associated with
socioeconomic class, the message for daily practice would
be unchanged, i. e. that the prevalence of insufficient sec-
ondary prevention is highest among ethnic minority groups
and that they may require more intensive support. Finally,
HELIUS included equivalent numbers of participants from
each ethnic group; therefore, the overall findings may not be
similar to those of a random sample from the same overall
population.
Conclusion
We found large treatment gaps regarding risk factor con-
trol in secondary prevention in the majority of individu-
als with CVD, with significant differences between ethnic
groups. Overall, the use of secondary preventive medication
is low, and markedly lower than reported in recent Euro-
pean surveys. Almost no patients (2%) have optimal risk
factor control, with a mean of three out of six risk fac-
tors off target. While there is variation in the prevalence
of risk factors and the use of prevention medication be-
tween ethnic groups, new initiatives should probably first
aim to increase the overall quality of secondary prevention,
regardless of ethnicity.
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